Fresh-to-market companies

Why it matters

• Pulmonary fibrosis affects ~100,000 Americans with limited treatment options
• Inhaled delivery may reduce systemic side effects vs oral pills
• $300M raise gives multi-year runway through key trial readouts

Risks

• • Pre-revenue biotech — value depends on trial data, not earnings
• • A single failed Phase 2/3 readout can cut the stock 50%+
• • Will need to raise more cash before any drug reaches market

Why it matters

• Silver demand rising from solar panel manufacturing and electronics
• Smaller miners can offer leveraged upside if metal prices climb
• Lower deal size ($50M) means tighter float and bigger price swings

Risks

• • Profits swing wildly with silver spot prices — a true commodity play
• • Mining costs, permits, and labor disputes can derail production
• • Small-cap miners often dilute shareholders with secondary offerings

Why it matters

• Targets rare diseases with high unmet need and orphan drug pricing power
• $200M raise + ~$667M market cap suggests strong institutional demand
• Antibody platform could spawn multiple drug candidates over time

Risks

• • Like all clinical biotechs, revenue is years away — burn rate matters
• • Rare-disease patient pools are small, capping peak sales
• • Competition from gene therapies in some bleeding disorders

Why it matters

• Mental health drug market is huge and underserved by recent innovation
• Backed by experienced biotech founders with prior successful exits
• Oral dosing could be a major advantage over IV-only competitors

Risks

• • Psychiatric drug trials are notoriously hard — placebo effects are large
• • FDA scrutiny on safety is intense for CNS drugs
• • Cash burn typical of clinical biotech — dilution likely before revenue

Why it matters

• $2.3B market cap with $117M revenue — actual operating business, not a SPAC
• Defense & space tech is one of the hottest IPO categories right now
• Government contracts provide recurring, sticky revenue streams

Risks

• • Heavy reliance on government budgets — politics can swing demand
• • Capital-intensive business: launching satellites is expensive
• • Competition from Planet Labs, BlackSky, and emerging private players

Why it matters

• $326M revenue makes this a real consumer business, not a story stock
• Wellness beverage category growing faster than traditional sodas
• Strong shelf presence in premium retail gives durable brand value

Risks

• • Cold-pressed juice is a crowded space — margins can compress
• • Tariffs and ingredient costs (organic produce) are volatile
• • Slow growth or a recession could squeeze premium-priced brands

Why it matters

• One of the most-watched IPOs of 2026 — celebrity-investor brand
• Asset managers earn fees on AUM, providing recurring revenue
• Down ~50% from IPO price — early investors are underwater

Risks

• • Heavy initial selloff signals weak post-IPO demand
• • Performance fees swing with hedge fund returns — lumpy earnings
• • Key-person risk: business value tied closely to one investor

Why it matters

• Hyperscalers (Amazon, Microsoft, Google) are signing nuclear deals to power AI
• Backed by Amazon as a strategic partner and customer
• Strong post-IPO performance shows real institutional demand

Risks

• • First commercial reactor still years from operation
• • Nuclear regulatory approval is slow and uncertain
• • Revenue today is modest vs the long-term opportunity

Why it matters

• Critical-minerals theme — US wants domestic supply away from China
• Sells into defense and semiconductor supply chains (sticky)
• Modest IPO premium — hasn't gone parabolic yet

Risks

• • Specialty-metals pricing is volatile
• • Customer concentration in a few aerospace and chip primes
• • Capex-heavy business — needs ongoing investment

Why it matters

• C-stores are recession-resilient — fuel, snacks, lottery, daily traffic
• Allsup's burritos are a regional cult brand with loyal customers
• Steady cash flows with real estate value behind the stores

Risks

• • Margins squeezed by higher labor costs and tobacco regulation
• • EV adoption could slowly erode fuel-sales gross profit
• • Competition from Buc-ee's, Wawa, and 7-Eleven in key markets

Why it matters

• Riding the 'drone warfare' theme accelerated by recent global conflicts
• DoD budget growth in autonomous systems is one of the strongest trends
• Up 50%+ post-IPO — market clearly likes the defense-tech story

Risks

• • Defense contracts are lumpy and depend on Congressional budgets
• • Already up sharply — late entrants pay a premium
• • Competition from Anduril, AeroVironment, and Kratos

Why it matters

• GLP-1 drugs are the biggest pharma category of the decade
• Strong post-IPO pop reflects investor appetite for obesity plays
• Could be a takeover target for Big Pharma needing pipeline depth

Risks

• • Late entrant in a market already dominated by Lilly and Novo Nordisk
• • Phase 3 trials are expensive — significant dilution risk
• • Pricing pressure from insurers as more GLP-1s come to market

Why it matters

• Proteomics is the next frontier after genomics for diagnostics
• Sells 'picks and shovels' to pharma and academic labs
• Strong reception suggests durable demand for the platform

Risks

• • Capital-equipment sales cycles are long and lumpy
• • Competing platforms from Olink, SomaLogic, and Quanterix
• • Pharma R&D budget cuts directly hit revenue

Why it matters

• Data center cooling demand is exploding alongside AI infrastructure
• Real cash-flowing business, not a speculative story
• HVAC names like Trane and Carrier have been multi-baggers

Risks

• • Cyclical exposure to commercial construction
• • Steel and copper input costs hit margins
• • Competition from larger, established HVAC players

Why it matters

• Up 6x since IPO — one of the standout performers of the year
• Drone swarming is widely seen as the future of warfare
• Real battlefield use cases differentiate it from PowerPoint competitors

Risks

• • Extreme valuation after 600%+ run — high downside risk
• • Lock-up expirations in coming months could flood the market with shares
• • Reliance on a small number of government and allied contracts

Why it matters

• Dominant position in a cash-heavy market still digitizing payments
• Profitable network-effects business with massive scale
• Rare large international fintech IPO accessible to US investors

Risks

• • Japanese regulatory environment can shift suddenly
• • FX exposure — yen weakness affects USD-reported results
• • Competition from LINE Pay, Rakuten Pay, and credit cards

Why it matters

• Pure-play on the 'AI for drug discovery' thesis
• Multiple programs in clinical development across cancer and immunology
• Down from IPO — possible discount entry for long-term believers

Risks

• • AI-discovered drugs still need to prove they work in humans
• • High cash burn typical of platform biotechs
• • Competition from Recursion, Insitro, and large-pharma AI efforts

Why it matters

• Direct beneficiary of utility data-center power demand from AI
• Recurring multi-year construction backlog provides visibility
• Up 50% post-IPO with broad institutional ownership

Risks

• • Policy risk if federal solar tax credits are reduced
• • Tariffs on imported panels squeeze project economics
• • Project execution risk on large fixed-price contracts